The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Blue chip stocks are under immense pressure amid the evolving trade tensions and tariff announcements around the globe.

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

We recently published a list of 11 Worst-Performing Blue Chip Stocks So Far in 2025. In this article, we are going to take a ...

More women than ever are being screened for cervical cancer, suggesting a policy change made just a few years ago is having a ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...